tiprankstipranks
AC Immune Advances in Alzheimer’s Trial, Secures Funding
Company Announcements

AC Immune Advances in Alzheimer’s Trial, Secures Funding

AC Immune SA (ACIU) has released an update.

Don't Miss our Black Friday Offers:

AC Immune SA announced receiving a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals, marking progress in the Phase 2b Re𝜏ain trial of its Alzheimer’s treatment, ACI-35.030. The payment was triggered by a swift prescreening rate for the trial, which aims to enroll around 500 pre-symptomatic Alzheimer’s patients and has already garnered a total of CHF 40 million in milestone payments. Highlighting the potential of its active immunotherapy candidate and robust financial position, AC Immune anticipates reaching transformative milestones within its three-year operational cash runway.

For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAC Immune Q3 2024: Strong Progress and Financial Turnaround
TheFlyAC Immune reports interim results from Phase 2 trial of ACI-7104.056
TipRanks Auto-Generated NewsdeskAC Immune’s Promising Trial Results for Parkinson’s Therapy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App